Coherus Oncology, Inc.
NASDAQ:CHRSBiotechnology
+$0.03 today
- Market cap
- $63.35M
- Beta
- 0.96
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.11
Volume 2.55M
Average 1.15M
CHRS Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Coherus Oncology, Inc.NASDAQ: CHRS
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses remains negative
Q1 FY2026 other income / expenses was -$784K, compared with -$1.96M a year earlier. Trailing-twelve-month other income / expenses was -$2.91M.
Context
- Other income / expenses amounted to 8.5% of revenue in FY2025, down 44.0 pp from a year earlier.
- Other income / expenses increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly other income / expenses holds near -$784K or moves back toward the trailing-twelve-month quarterly average of -$727.75K.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (3.59M) USD
- Year-over-year change
- -102.6%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.59M) | -102.6% |
| FY2024 | 2024-12-31 | 140.17M | +499.7% |
| FY2023 | 2023-12-31 | (35.07M) | -0.6% |
| FY2022 | 2022-12-31 | (34.87M) | -50.0% |
| FY2021 | 2021-12-31 | (23.24M) | — |
Other Income / Expenses vs competitors
How CHRS compares with its peers on the latest reported figures
- CHRS's LTM Mar 2026 other income / expenses of -$2.91M is the 7th highest of the 11 companies compared; the peer median is $1.58M.
- Its year-over-year change of +59.5% is the 3rd highest of 11, against a peer median of -20.3%.
- Other income / expenses amounts to 6.2% of revenue for CHRS, versus a peer median of 22.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.16M | -24.2% | — | 29.2% | |
| LTM Mar 2026 | $6.75M | +12.2% | +85.7% | — | |
| LTM Mar 2026 | $4.56M | +71.8% | +107.2% | 15.8% | |
| LTM Mar 2026 | $4.17M | -16.4% | -23.0% | 7.5% | |
| LTM Sep 2026 | $3.68M | +270.3% | +29.5% | — | |
| LTM Mar 2026 | -$526K | -199.8% | — | 0.7% | |
| LTM Mar 2026 | -$2.91M | +59.5% | — | 6.2% | |
| LTM Mar 2026 | -$5.41M | -104.4% | — | 9176.3% | |
| LTM Mar 2026 | -$6.03M | +17.5% | — | 7.7% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -$6.67M | -1912.5% | — | 342.2% |
| LTM Mar 2026 | -$13.7M | -653.1% | — | 39.6% | |
| Peer median (excluding CHRS) | $1.58M | -20.3% | +57.6% | 22.5% | |
Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 326.55M | 211.04M | 257.24M | 266.96M | 42.17M |
| Cost of Revenue | 57.59M | 70.08M | 158.99M | 117.55M | 17.74M |
| Gross Profit | 268.96M | 140.96M | 98.25M | 149.41M | 24.43M |
| Gross Margin | 82.4% | 66.8% | 38.2% | 56.0% | 57.9% |
| Research & Development | 363.11M | 199.36M | 109.44M | 93.34M | 104.96M |
| Selling, General & Admin | 169.71M | 198.48M | 185.62M | 150.44M | 99M |
| Operating Expenses | 532.82M | 397.84M | 301.45M | 261.07M | 203.97M |
| Depreciation & Amortization | 3.45M | 3.7M | 3.79M | 5.28M | 3.92M |
| EBITDA | (260.69M) | (255.58M) | (193.94M) | 60.94M | (170.2M) |
| EBITDA Margin | -79.8% | -121.1% | -75.4% | 22.8% | -403.6% |
| Operating Income | (263.86M) | (256.88M) | (203.2M) | (111.67M) | (179.53M) |
| Operating Margin | -80.8% | -121.7% | -79.0% | -41.8% | -425.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 22.96M | 32.47M | 40.54M | 27.16M | 9M |
| Other Income / Expenses | (23.24M) | (34.87M) | (35.07M) | 140.17M | (3.59M) |
| Income Before Tax | (287.1M) | (291.75M) | (238.27M) | 28.51M | (183.12M) |
| Pre-Tax Margin | -87.9% | -138.2% | -92.6% | 10.7% | -434.2% |
| Income Tax Expense | 0 | 0 | (380K) | 0 | 0 |
| Net Income | (287.1M) | (291.75M) | (237.89M) | 28.51M | (170.29M) |
| Net Margin | -87.9% | -138.2% | -92.5% | 10.7% | -403.8% |
| EPS (Basic) | (3.81) | (3.76) | (2.53) | 0.25 | (1.45) |
| EPS (Diluted) | (3.81) | (3.76) | (2.53) | 0.25 | (1.45) |
| Weighted Avg Shares | 75.45M | 77.63M | 94.16M | 114.55M | 120.37M |
| Weighted Avg Shares (Diluted) | 75.45M | 77.63M | 94.16M | 114.83M | 120.37M |
Coherus Oncology, Inc.
NASDAQ:CHRS
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.